Compare Amgen, Inc. (AMGN) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Realty Income Corp — how do they compare? Amgen, Inc. trades at $412.75 (market cap $224.14B), while Realty Income Corp trades at $62.17 (market cap $58.56B). The key difference: Amgen, Inc. is far larger — about 3.8× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (5.25%). Which is the better fit depends on your goals.
| AMGN | O | |
|---|---|---|
Market Cap | $224.14B | $58.56B |
Sector | Health | Real Estate |
52-Week High | $417.20 | $67.56 |
52-Week Low | $271.18 | $55.93 |
Enterprise Value | $267.45B | $89.19B |
Dividend Yield | 2.43% | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Realty Income (O) trades at $61.89, down 0.99% for the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported Q2 2026 EPS of $0.37, missing the $0.3977 estimate, but raised full-year AFFO guidance. Recent news highlights a $875 million convertible notes offering and a $6 billion hyperscale data center joint venture, supporting growth initiatives amid a 98.8% portfolio occupancy rate.
Outlook remains supported by dividend growth—115 consecutive quarterly increases—and a $10 billion investment target, though elevated debt levels and interest rate sensitivity pose risks. Analysts maintain a consensus price target of $67.29, implying ~9% upside, with 41% buy ratings reflecting cautious optimism for the REIT's income stability and expansion into data centers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
